Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Results of PONDx, a prospective multicenter study of the Oncotype DX® breast cancer assay: Real-life utilization and decision impact in French clinical practice
Elsa Curtit, Jean-Michel Vannetzel, Jean‐Claude Darmon, et al.
The Breast (2019) Vol. 44, pp. 39-45
Closed Access | Times Cited: 17

Showing 17 citing articles:

Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer
Yahiya Y. Syed
Molecular Diagnosis & Therapy (2020) Vol. 24, Iss. 5, pp. 621-632
Closed Access | Times Cited: 53
Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review
Gillian Parker, Sarah C. Hunter, Samer Ghazi, et al.
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0280582-e0280582
Open Access | Times Cited: 11
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 26
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.

PubMed (2020) Vol. 20, Iss. 10, pp. 1-234
Closed Access | Times Cited: 24
Real-world use of multigene signatures in early breast cancer: differences to clinical trials
Luca Licata, Rita De Sanctis, Andrea Vingiani, et al.
Breast Cancer Research and Treatment (2024) Vol. 205, Iss. 1, pp. 39-48
Open Access | Times Cited: 2
CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario
Satish Sankaran, Jyoti Bajpai Dikshit, Chandra Sv, et al.
Indian Journal of Surgical Oncology (2019) Vol. 12, Iss. S1, pp. 21-29
Open Access | Times Cited: 17
Is radiomic MRI a feasible alternative to OncotypeDX® recurrence score testing? A systematic review and meta-analysis
Matthew G. Davey, Martin S. Davey, Éanna J. Ryan, et al.
BJS Open (2021) Vol. 5, Iss. 5
Open Access | Times Cited: 10
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
Vladislav Berdunov, Steve Millen, Andrew Paramore, et al.
ClinicoEconomics and Outcomes Research (2022) Vol. Volume 14, pp. 619-633
Open Access | Times Cited: 6
Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis
Elsa Curtit, M. Bellanger, Virginie Nerich, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
Zohair Selmani, Chloé Molimard, Alexis Overs, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 3
The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx
Michał Jarząb, Maria Litwiniuk, Paige Innis, et al.
Współczesna Onkologia (2024) Vol. 28, Iss. 3, pp. 245-252
Open Access
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial
Luca Livraghi, Francesca Martella, Matteo Ghilli, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115108-115108
Closed Access
Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study
Antonio Llombart‐Cussac, Antonio Antón-Torres, Beatriz Rojas, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1529-1529
Open Access | Times Cited: 1
Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
Soong June Bae, Sung Gwe Ahn, Jung Hwan Ji, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4003-4003
Open Access | Times Cited: 3
Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
Weiqi Gao, Lin Lin, Xiaochun Fei, et al.
Journal of Cancer (2020) Vol. 11, Iss. 9, pp. 2509-2517
Open Access | Times Cited: 2
Real-world use of multigene signatures in early breast cancer: differences to clinical trials
Luca Licata, Rita De Sanctis, Andrea Vingiani, et al.
Research Square (Research Square) (2023)
Open Access
Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.
Zohair Selmani, Chloé Molimard, Alexis Overs, et al.
Research Square (Research Square) (2021)
Open Access
Page 1

Scroll to top